Fan Mu

Boston
Education
Ph.D., epidemiology, Harvard University; M.S., epidemiology, Harvard University; M.B.B.S., medicine, Peking University
Summary of Experience
Dr. Mu specializes in the application of advanced epidemiologic methodologies and biostatistical techniques to address a wide array of analytical questions in health care involving evaluation, decision making, and strategy. She has broad experience designing and implementing advanced and innovative data analytics and solutions for life sciences companies. Dr. Mu’s expertise includes real-world evidence development, database analyses, chart review studies, survey research, predictive analytics, systematic and targeted literature reviews, indirect comparisons, and health economic modeling. She has broad experience developing strategies and conducting research to assess the clinical, economic, and humanistic impacts of diseases and treatments in a range of therapeutic areas, including nephrology, immunology, psychiatry, oncology, dermatology, gynecology, and virology. She has consulted to numerous life sciences companies on both novel pipeline agents and products on the market. Dr. Mu’s work has supported health care payers and clinical decision makers in both US and global markets. Her research has been published in peer-reviewed journals and presented at clinical and economic research conferences.
Selected Cases
Selected Publishing
-
Real-world effectiveness of benralizumab: results from the ZEPHYR 1 Study
Annals of Allergy, Asthma & Immunology, 2022
2022Chung Y, Katial R, Mu F, Cook E, Young J, Yang D, Betts K, Carstens D
-
Five-Year Estimated Glomerular Filtration Rate in Adults with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study
Advances in Therapy, 2022
2022Ayodele O, Rejnmark L, Mu F, Lax A, Berman R, Swallow E, Gosmanova EO
-
The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States
Advances in Therapy, 2022
2022Woolley M, Cook EE, Mu F, Betts KA, Billmyer E, Yim E, Chen J, Wu EQ
-
-
Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study
Advances in Therapy, 2022
2022Ayodele O, Mu F, Berman R, Swallow E, Rejnmark L, Gosmanova EO, Kaul S
-
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
The Journal of Headache and Pain, 2022
2022Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R
-
Inpatient Management and Post-Discharge Outcomes of Hyperkalemia
Hospital Practice, 2021
2021Davis J, Israni R, Mu F, Cook E, Szerlip H, Uwaifo G, Fonseca V, Betts K
-
Risk of Chronic Kidney Disease in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1-84) Compared With a Historical Control Cohort
European Congress of Endocrinology, 2021
2021Gosmanova EO, Ayodele O, Sherry N, Mu F, Briggs A, Swallow E, Rejnmark L
-
Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support
Clinical Nutrition ESPEN, 2021
2021Chen K, Joly F, Mu F, Kelkar SS, Olivier C, Xie J, Seidner DL
-
Determinants of Hyperkalemia Progression Among Patients with Mild Hyperkalemia
Advances in Therapy, 2021
2021Israni R, Betts KA, Mu F, Davis J, Wang J, Anzalone D, Uwaifo GI, Szerlip H, Fonseca V, Wu E
-
Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and Hyperkalemia
Advances in Therapy, 2021
2021Cook EE, Davis J, Israni R, Mu F, Betts KA, Anzalone D, Yin L, Szerlip H, Uwaifo GI, Fonseca V, Wu EQ
-
The Impact of Antipsychotic Dose Reduction on Clinical Outcomes and Health Care Resource Use Among Medicare Patients with Schizophrenia
Clinical Drug Investigation, 2021
2021Zichlin ML, Mu F, Leo S, Ayyagari R
-
Prevalence and economic burden of hyperkalemia in the United States Medicare population
Current Medical Research and Opinion
2020 -
Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesia
BMC Psychiatry, 2020
2020Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B
-
Postdischarge Health Care Costs and Readmission in Patients With Hyperkalemia-Related Hospitalizations
Kidney International Reports, 2020
2020 -
Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders
Journal of Medical Economics, 2020
2020Ayyagari R, Thomason D, Mu F, Philbin M, Carroll B
-
Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era
Kidney Medicine, 2020
2020Cizman B, Smith HT, Camejo RR, Casillas L, Dhillon H, Mu F, Wu E, Xie J, Zuckerman P, Coyne D
-
The long-term direct and indirect economic burden among Parkinson's disease caregivers in the United States
Movement Disorders. 2019 Feb;34(2):236-245
2019Martinez-Martin P, Macaulay D, Jalundhwala YJ, Mu F, Ohashi E, Marshall T, Sail K
-
Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure
Journal of Parenteral and Enteral Nutrition, 2019
2019Chen K, Mu F, Xie J, Kelkar SS, Olivier C, Signorovitch J, Jeppesen PB
-
The prevalence of hyperkalemia in the United States
Current Medical Research and Opinion. 2018 Jun;34(6):971-978
2018 -
The Cost of Hyperkalemia in the United States
Kidney Int Rep. Mar 2018;3(2):385-393
2018 -
Impact of Hidradenitis Suppurativa on Work Loss, Indirect Costs and Income
British Journal of Dermatology, 2018
2018Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J
News
-
July 19, 2022
-
April 5, 2022
-
August 18, 2021
-
July 20, 2021
-
December 21, 2020
-
October 5, 2020